Results for Chemicals & Small Molecules ( 97556 )
- From: DKK818.00
DRB18 (Legacy Tebubio ref. 282T22317). DRB18 is a highly effective pan-class inhibitor of glucose transporter proteins (GLUT). It significantly modulates energy-related metabolism in A549 cells by inducing alterations in the abundance of metabolites associated with glucose-related pathways. DRB18 exerts its effects by promoting G1/S phase arrest, increasing oxidative stress, and prompting necrotic cell death, ultimately displaying notable anti-tumor activity [1].
- Ref: T22318Sizes: 1 mg, 5 mg, 25 mg, 100 mg, 50 mg, 10 mg, 2 mg, 1 mL * 10 mM (in DMSO)
EEDi-5285 (Legacy Tebubio ref. 282T22322). EEDi-5285, an orally active and highly potent inhibitor targeting embryonic ectoderm development (EED) protein, exhibits anti-cancer activity. It demonstrates exceptional efficacy with an IC50 value of 0.2 nM, indicating robust binding affinity to the EED protein.
- From: DKK270.00
Enoxaparin sodium (Legacy Tebubio ref. 282T22323). Enoxaparin sodium is a low-molecular-weight heparin (LMWH) that has recently been approved by the US FDA for use in patients with medically managed ST-segment myocardial infarction (STEMI), or STEMI with subsequent percutaneous coronary intervention (PCI). It binds to and potentiates the action of antithrombin, and inhibits coagulation factors XIa, IXa, Xa and IIa (thrombin), thereby preventing formation of blood clots.
- Ref: T22324Sizes: 1 mg, 5 mg, 25 mg, 100 mg, 50 mg, 10 mg, 2 mg, 1 mL * 10 mM (in DMSO)From: DKK518.00
Ensartinib hydrochloride (Legacy Tebubio ref. 282T22324). Ensartinib hydrochloride (X-396 dihydrochloride) is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of known crizotinib-resistant ALK mutations. It potently inhibits both wild-type ALK and ALK variants (C1156Y, F1174, G1202R, L1196M, S1206R, and T1151 mutants) with in vitro IC50s of <4 nM.
- Ref: T22325Sizes: 1 mg, 5 mg, 25 mg, 100 mg, 50 mg, 10 mg, 1 mL * 10 mM (in DMSO)